Stoke Therapeutics (STOK) Cash from Investing Activities Growth (1y) (2019 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Cash from Investing Activities Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 26.37% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | -89.24% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 106.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 106.07% |
| Mar 31, 2026 | 271.88% |
| Dec 31, 2025 | -7,555.56% |
| Sep 30, 2025 | 130.31% |
| Jun 30, 2025 | -68.19% |
| Mar 31, 2025 | 36.48% |
| Dec 31, 2024 | -94.46% |
| Sep 30, 2024 | -305.27% |
| Jun 30, 2024 | -476.08% |
| Mar 31, 2024 | -81.18% |
| Dec 31, 2023 | -34.32% |
| Sep 30, 2023 | -78.27% |
| Jun 30, 2023 | 15,977.40% |
| Mar 31, 2023 | 139.10% |
| Dec 31, 2022 | 90.64% |
| Sep 30, 2022 | 1,377.81% |
| Jun 30, 2022 | 100.18% |
| Mar 31, 2022 | -66,459.80% |
| Dec 31, 2021 | 13,207.78% |
| Sep 30, 2021 | -1,856.88% |